


Excluded Studies

1. RCTs

Study	Year	Reason for exclusion
Dimopoulos et al. [1]	2013	Does not report outcome of interest
Gertz et al. [2]	1995	Investigates different doses of the same intervention.
Jagannath et al. [3]	2004	Investigates different doses of the same intervention.
Moreau et al. [4]	2012	Investigates different doses of the same intervention. Does not report outcome of interest
Moreau et al. [5]	2008	Investigates different doses of the same intervention. Does not report outcome of interest
Richardson et al. [6]	2006	Investigates different doses of the same intervention.
Schey et al. [7]	2013	Investigates different doses of the same intervention.
Yakoub-Agha et al. [8]	2011	Investigates different doses of the same intervention.
Zonder et al. [9]	2015	Does not report outcome of interest.
Hajek et al. [10]	2017	Not connected to network

2. Non-RCTs



1. Dimopoulos, M.A., et al., *Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma*. *Haematologica*, 2013. **98**(8): p. 1264-1272.
2. Gertz, M.A., et al., *Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study*. *American journal of clinical oncology*, 1995. **18**(6): p. 475-480.
3. Jagannath, S., et al., *A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma*. *British journal of haematology*, 2004. **127**(2): p. 165-172.
4. Moreau, P., et al., *A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma*. 2012, American Society of Clinical Oncology.
5. Moreau, P., et al., *Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma*. *haematologica*, 2008. **93**(12): p. 1908-1911.
6. Richardson, P.G., et al., *A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma*. *Blood*, 2006. **108**(10): p. 3458-3464.
7. Yong, K.L., et al., *Identifying an optimally effective but tolerable dose of bendamustine in combination with thalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma*. 2013, Am Soc Hematology.
8. Yakoub-Agha, I., et al., *Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome*. *European journal of haematology*, 2012. **88**(3): p. 249-259.
9. Zonder, J.A., et al., *Phase 2 study of carfilzomib (CFZ) with or without filanesib (FIL) in patients with advanced multiple myeloma (MM)*. 2015, Am Soc Hematology.
10. Hájek, R., et al., *A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)*. *Leukemia*, 2017. **31**(1): p. 107.